A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma

References

• Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006; 100:1139 - 51; http://dx.doi.org/10.1016/j.rmed.2006.03.031; PMID: 16713224
   PubMed Web of Science ®Google Scholar
• Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, Smurthwaite L. The biology of IGE and the basis of allergic disease. Annu Rev Immunol 2003; 21:579 - 628; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141103; PMID: 12500981
   PubMed Web of Science ®Google Scholar
• Chang TW, Wu PC, Hsu CL, Hung AF. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv Immunol 2007; 93:63 - 119; http://dx.doi.org/10.1016/S0065-2776(06)93002-8; PMID: 17383539
   PubMed Web of Science ®Google Scholar
• Wilcock LK, Francis JN, Durham SR. IgE-facilitated antigen presentation: Role in allergy and the influence of allergen immunotherapy. Immunol Allergy Clin North Am 2006; 26:333,47, viii-ix.
   Google Scholar
• Li H, Nowak-Wegrzyn A, Charlop-Powers Z, Shreffler W, Chehade M, Thomas S, Roda G, Dahan S, Sperber K, Berin MC. Transcytosis of IgE-antigen complexes by CD23a in human intestinal epithelial cells and its role in food allergy. Gastroenterology 2006; 131:47 - 58; http://dx.doi.org/10.1053/j.gastro.2006.03.044; PMID: 16831589
   PubMed Web of Science ®Google Scholar
• Palaniyandi S, Tomei E, Li Z, Conrad DH, Zhu X. CD23-dependent transcytosis of IgE and immune complex across the polarized human respiratory epithelial cells. J Immunol 2011; 186:3484 - 96; http://dx.doi.org/10.4049/jimmunol.1002146; PMID: 21307287
   PubMed Web of Science ®Google Scholar
• Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, et al. IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 2007; 179:2832 - 43; PMID: 17709497
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004; 59:701 - 8; http://dx.doi.org/10.1111/j.1398-9995.2004.00533.x; PMID: 15180756
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184 - 90; http://dx.doi.org/10.1067/mai.2001.117880; PMID: 11496232
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, Buhl R, O’Brien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254 - 61; http://dx.doi.org/10.1183/09031936.01.00092101; PMID: 11529281
   PubMed Web of Science ®Google Scholar
• Lanier B. Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease. Allergy Asthma Proc 2006; 27:Suppl 1 S37 - 42; PMID: 16722331
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101:1483 - 92; http://dx.doi.org/10.1016/j.rmed.2007.01.011; PMID: 17339107
   PubMed Web of Science ®Google Scholar
• Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996; 14:309 - 14; http://dx.doi.org/10.1038/nbt0396-309; PMID: 9630891
   PubMed Web of Science ®Google Scholar
• Lloyd C, Lowe D, Edwards B, Welsh F, Dilks T, Hardman C, Vaughan T. Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel 2009; 22:159 - 68; http://dx.doi.org/10.1093/protein/gzn058; PMID: 18974080
   PubMed Web of Science ®Google Scholar
• Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992; 224:487 - 99; http://dx.doi.org/10.1016/0022-2836(92)91010-M; PMID: 1560463
   PubMed Web of Science ®Google Scholar
• Bracher M, Gould HJ, Sutton BJ, Dombrowicz D, Karagiannis SN. Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis. J Immunol Methods 2007; 323:160 - 71; http://dx.doi.org/10.1016/j.jim.2007.04.009; PMID: 17531261
   PubMed Web of Science ®Google Scholar
• Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature 2000; 406:259 - 66; http://dx.doi.org/10.1038/35018500; PMID: 10917520
   PubMed Web of Science ®Google Scholar
• Holdom MD, Davies AM, Nettleship JE, Bagby SC, Dhaliwal B, Girardi E, Hunt J, Gould HJ, Beavil AJ, McDonnell JM, et al. Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI. Nat Struct Mol Biol 2011; 18:571 - 6; http://dx.doi.org/10.1038/nsmb.2044; PMID: 21516097
   PubMed Web of Science ®Google Scholar
• Dhaliwal B, Yuan D, Pang MO, Henry AJ, Cain K, Oxbrow A, Fabiane SM, Beavil AJ, McDonnell JM, Gould HJ, et al. Crystal structure of IgE bound to its B-cell receptor CD23 reveals a mechanism of reciprocal allosteric inhibition with high affinity receptor FcεRI. Proc Natl Acad Sci U S A 2012; 109:12686 - 91; http://dx.doi.org/10.1073/pnas.1207278109; PMID: 22802656
   PubMed Web of Science ®Google Scholar
• Demeule B, Shire SJ, Liu J. A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation. Anal Biochem 2009; 388:279 - 87; http://dx.doi.org/10.1016/j.ab.2009.03.012; PMID: 19289095
   PubMed Web of Science ®Google Scholar
• Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, Deniz Y. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin 2003; 19:491 - 8; http://dx.doi.org/10.1185/030079903125002171; PMID: 14594521
   PubMed Web of Science ®Google Scholar
• MacGlashan DW Jr., W. MD. Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables. J Allergy Clin Immunol 1993; 91:605 - 15; http://dx.doi.org/10.1016/0091-6749(93)90266-I; PMID: 7679683
   PubMed Web of Science ®Google Scholar
• Corren J, Shapiro G, Reimann J, Deniz Y, Wong D, Adelman D, Togias A. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J Allergy Clin Immunol 2008; 121:506 - 11; http://dx.doi.org/10.1016/j.jaci.2007.11.026; PMID: 18269927
   PubMed Web of Science ®Google Scholar
• Johansson SG, Nopp A, Oman H, Ankerst J, Cardell LO, Grönneberg R, Matsols H, Rudblad S, Strand V, Stålenheim G. The size of the disease relevant IgE antibody fraction in relation to ‘total-IgE’ predicts the efficacy of anti-IgE (Xolair) treatment. Allergy 2009; 64:1472 - 7; http://dx.doi.org/10.1111/j.1398-9995.2009.02051.x; PMID: 19393000
   PubMed Web of Science ®Google Scholar
• Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy 2009; 64:1780 - 7; http://dx.doi.org/10.1111/j.1398-9995.2009.02119.x; PMID: 19627273
   PubMed Web of Science ®Google Scholar
• Minter RR, Cohen ES, Wang B, Liang M, Vainshtein I, Rees G, et al. Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis. Br J Pharmacol 2012; In press PMID: 22913645
   PubMed Web of Science ®Google Scholar
• Sundberg EJ. 2. structural basis of antibody-antigen interactions. In: Reineke U, Schutkowski M, eds. Epitope Mapping Protocols. 2nd ed.: Humana Press, 2009.
   Google Scholar
• Sayers I, Cain SA, Swan JR, Pickett MA, Watt PJ, Holgate ST, Padlan EA, Schuck P, Helm BA. Amino acid residues that influence Fc epsilon RI-mediated effector functions of human immunoglobulin E. Biochemistry 1998; 37:16152 - 64; http://dx.doi.org/10.1021/bi981456k; PMID: 9819207
   PubMed Web of Science ®Google Scholar
• Johansson SG, Oman H, Nopp A, Pettersson S. The importance of IgE antibody levels in anti-IgE treatment. Allergy 2006; 61:1216 - 9; http://dx.doi.org/10.1111/j.1398-9995.2006.01172.x; PMID: 16942572
   PubMed Web of Science ®Google Scholar
• Ankerst J, Nopp A, Johansson SG, Adédoyin J, Oman H. Xolair is effective in allergics with a low serum IgE level. Int Arch Allergy Immunol 2010; 152:71 - 4; http://dx.doi.org/10.1159/000260086; PMID: 19940508
   PubMed Web of Science ®Google Scholar
• Hamilton RG, MacGlashan DW Jr., Saini SS. IgE antibody-specific activity in human allergic disease. Immunol Res 2010; 47:273 - 84; http://dx.doi.org/10.1007/s12026-009-8160-3; PMID: 20066506
   PubMed Web of Science ®Google Scholar
• Bachert C, van Steen K, Zhang N, Holtappels G, Cattaert T, Maus B, et al. Specific IgE against staphylococcus aureus enterotoxins: An independent risk factor for asthma. J Allergy Clin Immunol 2012; 130:376,381 e8.
   Google Scholar
• de Llano LP, Vennera MdelC, Álvarez FJ, Medina JF, Borderías L, Pellicer C, González H, Gullón JA, Martínez-Moragón E, Sabadell C, et al, Spanish Registry. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma 2013; 50:296 - 301; http://dx.doi.org/10.3109/02770903.2012.757780; PMID: 23350994
   PubMed Web of Science ®Google Scholar
• Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L. Long-term benefits of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol 2011; 7:9; http://dx.doi.org/10.1186/1710-1492-7-9; PMID: 21609447
   PubMed Web of Science ®Google Scholar
• Takhar P, Corrigan CJ, Smurthwaite L, O’Connor BJ, Durham SR, Lee TH, Gould HJ. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol 2007; 119:213 - 8; http://dx.doi.org/10.1016/j.jaci.2006.09.045; PMID: 17208604
   PubMed Web of Science ®Google Scholar
• van den Berge M, Pauw RG, de Monchy JG, van Minnen CA, Postma DS, Kerstjens HA. Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest 2011; 139:190 - 3; http://dx.doi.org/10.1378/chest.10-0128; PMID: 21208879
   PubMed Web of Science ®Google Scholar
• Lowe PJ, Tannenbaum S, Gautier A, Jimenez P. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009; 68:61 - 76; http://dx.doi.org/10.1111/j.1365-2125.2009.03401.x; PMID: 19660004
   PubMed Web of Science ®Google Scholar
• Braunstahl GJ, Chen CW, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the ‘real-world’ effectiveness of omalizumab in allergic asthma. Respir Med 2013; 107:1141 - 51; http://dx.doi.org/10.1016/j.rmed.2013.04.017; PMID: 23721684
   PubMed Web of Science ®Google Scholar
• Ikeyama S, Nakagawa S, Arakawa M, Sugino H, Kakinuma A. Purification and characterization of IgE produced by human myeloma cell line, U266. Mol Immunol 1986; 23:159 - 67; http://dx.doi.org/10.1016/0161-5890(86)90038-6; PMID: 3702874
   PubMed Web of Science ®Google Scholar
• Persic L, Roberts A, Wilton J, Cattaneo A, Bradbury A, Hoogenboom HR. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 1997; 187:9 - 18; http://dx.doi.org/10.1016/S0378-1119(96)00628-2; PMID: 9073061
   PubMed Web of Science ®Google Scholar
• Rossmann MG. The Molecular Replacement Method. New York: Gordon & Breach, 1972.
   Google Scholar
• Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63:548 - 61; http://dx.doi.org/10.1111/j.1365-2125.2006.02803.x; PMID: 17096680
   PubMed Web of Science ®Google Scholar
• Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, Deniz Y, Lowman H, Fielder P, Visich J, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J 2008; 10:425 - 30; http://dx.doi.org/10.1208/s12248-008-9045-4; PMID: 18686041
   PubMed Web of Science ®Google Scholar